Form 4: Inovio Pharmaceuticals, Inc. (INO), Yarno Wendy L, transaction 12/05/2020
Summary
Wendy Yarno, a Director of INOVIO PHARMACEUTICALS, INC. [ INO ], reports on this Form 4 that 4,090 Restricted Stock Units converted into 4,090 shares of Common Stock (code M) on 12/05/2020, leaving 28,453 shares owned directly. The explanation says each restricted stock unit is a contingent right to receive one share, and that the 12,270 units vested in portions of 4,090 shares on December 5, 2018, December 5, 2019 and December 5, 2020. Vested units can be settled in shares, cash or a combination of both. The form is signed /s/ Wendy Yarno, 12/07/2020.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 4: Inovio Pharmaceuticals, Inc. (INO), Yarno Wendy L, transaction 12/05/2020.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ino-4-filed2020-12-07-0001055726-20-000054-f1a2dc9107/
, SHA-256 6a42ce37e24739cea4c12875e5c756e316e88b01d876bf4bb39b5ea62955e373.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * YARNO WENDY L (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | YARNO WENDY L | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE | SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 12/05/2020 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock | 12/05/2020 | M | 4,090 | A | (1) | 28,453 | D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Restricted Stock Unit | (1) | 12/05/2020 | M | 4,090 | (1) | (1) | Common Stock | 4,090 | $ 0 | 0 | D Explanation of Responses: 1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on December 5, 2018; 4,090 shares vested on December 5, 2019; 4,090 shares vested on December 5, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Remarks: /s/ Wendy Yarno | 12/07/2020 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_INO_4_filed2020-12-07_0001055726-20-000054.xml
- Size
- 16,298 bytes
- SHA-256
- 6a42ce37e24739cea4c12875e5c756e316e88b01d876bf4bb39b5ea62955e373
- Original
- www.sec.gov